Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How do you know that Dr. Missling has all the data?
A week ago he didn't have all of it -
“Safety is a key requirement for a potential drug approval and we believe that this extension, which is now already the second of this trial, is an important step forward for patients, caregivers and physicians, who have asked for continued access to ANAVEX 2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “While we are waiting for longitudinal effect data of ANAVEX 2-73 over an extended period of time, the positive dose-response in PART A is an encouraging step and also consistent with the fast mode of action of the sigma-1 receptor.“
http://www.anavex.com/?news=anavex-announces-two-year-clinical-extension-study-of-anavex-2-73-and-presents-phase-2a-dose-response-analysis-at-aat-conference
Absolutely! The Missling era will go down in the history books.
Companies evolve. AVXL became a totally different Company after Missling became CEO. He attracted quality board members and a world class SAB. Missling raised capital for clinical trials, which have demonstrated A2-73's excellent safety profile and remarkable efficacy sooner than anticipated.
To dwell on the pre-Missling era is a fool's game. Of course, hit piece writers play the fool's game. It's the best they can come up with to attack AVXL and prey on the gullible.
AF has been negative on CPXX. Stock closed at $1.68 and just hit $9.49 afterhours. AF was negative because of small market cap. Another on AF's hit list shot up couple weeks ago. The guy is useless.
I believe that an A2-73 Plus patent would have extended the duration of A2-73's protection, when combined with donepezil.
Long term, I think Anavex's plan is to gain FDA approval for A2-73 for Alzheimer's Disease. Then attempt to replace A2-73 with A3-71 which has patent protection until at least 2033.
Anavex would not need a patent to sell Anavex Plus. Just FDA approval.
If A2-73 is as good as A2-73 + donepezil, then donepezil's baggage (side effects & dismal longitudinal effect history) are removed from A2-73's back. Beautiful scenario!
It's soooooo good to know that Anavex has 2 drugs with the potential to make a huge difference in patients lives and take investors to the promised land.
Due to the remarkable 5 week and interim 26 week data for A2-73 alone in humans, the Company has already started to back away from Anavex Plus in their PRs.
From PRs before last Thurday -
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
From the last 2 PRs. The above bolded portion is omitted -
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73 is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
I was referencing the 50,000 share dump by one trader.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121145755
The PR on Thursday told us that the 12 week data would not be released on Saturday. The market was fine with that until the last few minutes of trading on Friday.
We know why the share price dipped during the last few minutes Friday -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121145755
That's great!
The market knew on Thursday that the 12 week data would not be released on Saturday -
“Safety is a key requirement for a potential drug approval and we believe that this extension, which is now already the second of this trial, is an important step forward for patients, caregivers and physicians, who have asked for continued access to ANAVEX 2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “While we are waiting for longitudinal effect data of ANAVEX 2-73 over an extended period of time, the positive dose-response in PART A is an encouraging step and also consistent with the fast mode of action of the sigma-1 receptor.“
I know it's not over. I was replying to hooperg83's #1.
The 12 week data is coming. I'm not sweating it.
It appears that the full 12 week data wasn't ready for Athens. This is from the pre-conference PR -
“Safety is a key requirement for a potential drug approval and we believe that this extension, which is now already the second of this trial, is an important step forward for patients, caregivers and physicians, who have asked for continued access to ANAVEX 2-73,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “While we are waiting for longitudinal effect data of ANAVEX 2-73 over an extended period of time, the positive dose-response in PART A is an encouraging step and also consistent with the fast mode of action of the sigma-1 receptor.“
Great post from another board -
Most people here
by tredenwater2 • 2 hours 46 minutes ago
seem to be eager for the knockout punch by Missling. With the rapid price fluctuations of the past it seems to drive a sense of urgency by some to make that money back,....and then some. The science is unfolding in a monumental fashion for the whole BIO pharma and patient world to see in BABYSTEPS! This is not a race you want to over accelerate early on, kind of like the tortoise and the hare. I agree with others that the science will eventually support the price (in a major way), not the other way around. Dr. Missling is a seasoned BIO executive with EXCELLENT credentials. He has attracted the BEST AND BRIGHTEST scientists on his advisory board for the journey! He has MULTIPLE PH 1 trials in motion with ALZ being at the top in PH 2 PREPARING for PH 3! This is unprecedented territory so lets all take a deep breath, relax, and let the baby steps continue. This time next year will be a whole lot brighter with the hope it will bring to humanity GOD willing!
MY OPINION ONLY
PART B data includes the 12 week data.
This is what Dr. Missling said at the CEO and Investor Conference on February 9th -
Overall, what is the expected catalysts for this year? We have interesting data coming forward, which is the 12 & 26 week data. We will provide updates this quarter once we have data. We will also update the PK/PD data.
This can be heard at the 24 minute mark -
https://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm
Anavex 2-73: Confirmed Targeted Indications
Anxiety - Preclinical Validation
Depression - Preclinical Validation
Page 4 - http://www.anavex.com/files/2016-03-12_AAT_Anavex_Presentation_2016.pdf
I wasn't aware of these preclinical validations. Is this the first time that this has been disclosed?
Dr. Missling released what he said would be released. No surprise there. The biomarker summit on March 22nd looks like a good candidate for 12 week data -
Bman49ers Thursday, 02/18/16 04:22:22 PM
Re: ipulator_man post# 54248
Post # of 56618
I think it will be the biomarker summit 2016 in San Diego. Abstracts are still being accepted. Missling kept mentioning Biomarkers in his presentation and I think this was a breadcrumb from him.
https://www.gtcbio.com/conferences/biomarkers-summit-overview
McMagyar Monday, 02/29/16 07:41:41 AM
Re: None
Post # of 56618
I would think the fact that we KNOW, from preliminary data ALREADY RELEASED, that almost 80% of Patients (11 of 14) at 12 WEEKS showed the greatest response ever seen(this is not necessarily a factual statement, but I have not found any drug that had a better response at 12 WEEKS in previous testing), +3.21 on an ADAS-??? Scale at 12 Weeks..
Why are we regressing to a computer model when we have actual human data in hand? so let's extrapolate from the preliminary 12 WEEK data set, say 23 out of 30 Patients show a similar marked improvement at 12 weeks and then maintain that improvement over 26 weeks..that could be 1/2 a year of independent living..birthdays remembered, stories told, golf played, tea drank with the proper ingredients. names remembered..6 months is forever! As long as the safety profile continues to show minimal risk and only short term minimal discomfort, A2-73 has already shown more efficacy than anything that has ever been tried! And through BIOMARKER Improvement and the nature of A2-73 being preventive, the SOONER people start protecting their brains with A2-73 .perhaps,the better..This is why I think Anavex will release 12/26 WEEK Part B data at the BIOMARKER'S Conference in San Diego, March 22(?)..
Terrific post from another board -
Worst case scenarios?
by actioncaster_com • 8 hours ago Flag
.
At this point, there's really only two outlier scenarios that longs have to fear:
1. The entirety of this is an utter sham and Missling has been manufacturing a completely false narrative this entire time. Likelihood: extremely slim to nonexistant given the scientific publications corroborating the company's narrative and the researchers who've tacked their names to them. Not to mention that the ensuing legal onslaught would be massive and (for once) justified, and there's near zero incentive to invite that kind of woe upon oneself. If someone is driven by a profit motive above ethics, there are much easier ways to go about it (that have much less visibility or likelihood of repercussions) than making false statements as head of a public company.
2. 2-73 goes on to Phase III ***for AD*** and results (again, ***for AD***) don't materialize in a larger population as they have in Phase IIa/b (should be IIa, PART A & PART B). Likelihood: not impossible -HOWEVER-... we know several facts:
There is a real, confirmed mechanism of action with 2-73. Full stop. It affects significant cellular mechanisms (mechanisms which aren't solely associated with AD, more on that in a bit) and have a measurable micro and macro effect (recall Missling's salient observation that the minor dizziness reported is a fantastic indicator of this). Anecdotal evidence of an improvement in mood and disposition is extremely telling as well, if one understands the role other SIgma agonists out there play (I leave it to the reader to do some Googling for "Sigma agonist").
We also have the benefit of hindsight with respect to the groupthink that pervaded Alzheimer's research; the overabundance of amyloid plaque being misinterpreted as root cause vs what we now understand to be a symptom of a deeper underlying malfunction in the cellular machinery. We've seen all the pharma superstars throw everything they had at removal of amyloid plaque (to the exclusion of literally all else), as if wiping away sweat could somehow eliminate a malarial infection. And we've seen that approach fail, completely. Not all that surprising, in hindsight.
There are other, highly qualified posters who have gone into great detail over the past few months regarding the mechanisms of Alzheimer's disease and 2-73's mechanism(s) of action (do a board search for:
Excitotoxicity & Calcium Overload
Oxidative Stress
Endoplasmic Reticulum Stress
Reactive Gliosis)
There are compelling odds that A2-73's MOA could have a significant positive effect at mitigating the true underlying causes of Alzheimer's. It is *not* hard to believe that Big Pharma went, like a herd of lemmings, down a blind alley and overlooked a lone scientist who took a more productive path. The first half of that is confirmed already. BUT EVEN IF, at the conclusion of an expanded Phase III trial, A2-73's effects are not as phenomenal as early data suggests, the current Standard Of Care (Donepezil) is effectively snake oil. It does next to nothing to halt or even mitigate the progression of Alzheimer's (and forget about "cure"). **ANY** benefit seen from A2-73, **AT ALL**, would be massive, relative to the current, no-hope, no benefit SOC.
Other posters have observed the dollar amount of the market for Alzheimer's "treatments;" for those unfamiliar, it is positively massive. Let's further assume the worst and ignore the mounting likelihood that A2-73 will hit the (very wide, very close) target with Alzheimer's. A2-73 is NOT JUST ABOUT ALZHEIMER'S.
The list of indications where A2-73 could be effective is ever-expanding. First there was Parkinson's. Then epilepsy. Now Rett Syndrome. Any of these alone would be intriguing; all of them together is extremely compelling. And these are only diseases the company has prioritized; the probability A2-73 could impact Huntingtons, ALS, **depression** is significant, IMO. The likelihood of A2-73 being a one-trick pony becomes slimmer and slimmer the more one understands its neuroprotective effects.
There are some very vocal posters manufacturing all manner of frivolous, baseless, and intentionally misleading "risks" associated with AVXL. Some of these posters are incapable of seeing the big picture here, as laid out above. They have blindly taken a stance, based on (unrelated) past experience with microcap biotechs, that may have served them well on these past occasions. There are others that have some idea how financially treacherous their contrary position will likely turn out, over the long run. Still others are acutely aware of the upside potential here, and desperately want to accumulate at the lowest possible price (accomplished by achieving a critical mass of doubt in someone holding AVXL shares and compelling them to sell). All have real motivation to do what they do. Anyone new here, use this as an outline and research all these points for yourself. Traders, go ahead and trade. Investors, go ahead and invest. Don't let these clowns affect what you do, though. GL to all the sincere posters out there!
News has moved AVXL substantially higher in the past. On 7/21/15, AVXL closed at a post split price of $2.00. On 8/5/15, AVXL closed at $6.00.
A lot of good data has been reported since 7/22/15. I think we're due for some catch up share price appreciation.
Thanks. I hadn't thought about this and I agree -
No additional improvement in the plus arm is a surprise to me -
If 12 week data isn't released on Saturday, Dr. Missling may have another conference presentation planned for this month.
This is what Dr. Missling said at the CEO and Investor Conference on February 9th -
Overall, what is the expected catalysts for this year? We have interesting data coming forward, which is the 12 & 26 week data. We will provide updates this quarter once we have data. We will also update the PK/PD data.
This can be heard at the 24 minute mark -
https://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm
Spacing the release of data may be the plan.
Yes, it is good to see the extension. I was wrong regarding it. The Company must be seeing promising data from the patients that have completed 9 months and 12 months of the current trial.
I've got your placebo effect right here -
4. Of all the battery of tests which do you think most powerful for AD, and how did Anavex 2-73 perform in that test?
The One-back test (which measures working memory, a key domain of impairment in AD) within the Cogstate battery is the most difficult test, yet showed the greatest improvement. This outcome is unlikely to have been an artefact of any placebo effect...when placebo effects occur they are typically larger for the easier tests. In addition, whilst placebo effects are common with CNS sedative drugs, they are less likely to be present in tests of drugs used to enhance cognition...individuals cannot anticipate, or 'imagine' what a better score would consist of, and are unable to produce improved results through mere 'wishful thinking.'
This quote is from Dr. Macfarlane. He has been running Alzheimer's trials for 16 years.
http://seekingalpha.com/article/3672856-anavex-life-sciences-interview-dr-stephen-macfarlane
While we would all like to see A2-73's protection extended when it is combined with donepezil, it's important to realize that Anavex Plus can still be sold to patients if the patent is not issued.
Furthermore, only Anavex could do this as they have the rights to A2-73.
Why? donepezil is off-patent and Anavex owns the rights to A2-73.
To me, the only advantage of a Plus patent is that the time of protection would be extended.
I wouldn't be so sure of that. A2-73 and donepezil could be prescribed separately and equal Anavex Plus.
Thanks for the detailed explanation!
Dr. Christopher Missling answers patent questions here -
http://seekingalpha.com/article/3354415-interview-with-dr-christopher-missling-ceo-of-anavex?auth_param=d2ta:1ar4d6c:74ced639ac1ecb22d9cbea5192bcfa90
KKD - So, until you get the patent assigned to you, you cannot begin the Anavex Plus trial, correct?
CM - No. All patents are irrevocably assigned or owned by Anavex.
orveko_inc does an excellent job of covering the patent news. Here are his posts -
http://investorshub.advfn.com/boards/MemberPostsToBoard.aspx?userid=525667&boardid=11474
This is what Dr. Missling said at the CEO and Investor Conference on February 9th -
Overall, what is the expected catalysts for this year? We have interesting data coming forward, which is the 12 & 26 week data. We will provide updates this quarter once we have data. We will also update the PK/PD data.
This can be heard at the 24 minute mark -
https://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm
He didn't say we would get full 26 week data this quarter. In fact, that would be impossible. Ms Australia double checked and was sure that her relative had his end of 12 week tests during the first week of January. Add 14 weeks to that and the 26 week tests for him won't happen until mid April.
Don't worry about catalysts. Worry about your skill level.
INTL Thursday, 01/14/16 10:10:52 AM
Re: A deleted message
Post # of 55380
Yes Joshalex5!! Next leg down could be under .10.Lots of money vanishing from peoples accounts. WOW
Prana's drug was a good candidate for failure. It was not reversing the effects of Alzheimer's like A2-73, just possibly slowing progression.
Macfarlane's enthusiasm during the Prana trial was directed at one patient. Currently, his enthusiasm is for the whole trial.
Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo.
Hmmm, sure sounds like AVXL's lead trial investigator thinks the trial results are great. Of course, he has only been involved in 16 Alzheimer's trials, so what does he know?
http://seekingalpha.com/article/3672856-anavex-life-sciences-interview-with-dr-stephen-macfarlane
Five out of the 6 cogstate domains showed improvement, with 3 of these showing large effect sizes. The 'one-back' test within cogitate showed an effect size of 1.1 (meaning the standard distribution curve of the results was improved by 1.1 standard deviations, a huge effect size. A published meta-analysis of donepezil's benefit on the same test showed an effect size of 0.28. The significance of this particular change is underlined by the fact that 75% of our sample had already been taking a stable dose of donepezil for at least three months, so the improvements on the Cogitate battery (and on all the other cognitive outcome measures, were achieved over and above the gains our participants might already have achieved through being on donepezil. The same is true for the improvements noted on MMSE and ADCS-ADL, and the EEG markers (of which one ERP was statistically significant). I gather much is being made in certain circles that the remainder of the EEG markers, as well as the MMSE and ADCS-ADL scores failed to achieve statistical significance, but in a 5-week study of 32 patients it would almost have been beyond belief if this were to have been shown to be the case. The study was not powered to demonstrate significance, but the response on certain outcome measures was so marked that significance was achieved anyway (at a level of p=0.001 in the case of the Cogitate one-back task.
Here are comments on the trial data from people that know what they are talking about -
“While it is of prime importance to have confirmed that both the primary and secondary endpoints of the trial have been met, it is extremely encouraging to see the emergence of such strong cognitive signals after only 5 weeks of treatment. Such an outcome in a trial such as this is unprecedented in my experience, and the current results suggest that ANAVEX 2-73 could potentially make a significant difference in patients’ lives,” said Associate Professor Stephen Macfarlane, FRANZCP, Director of Aged Psychiatry at Alfred Health, who conducted the study. “We continue to receive extremely positive feedback about the effects of the drug from our study participants and their caregivers. The results justify a prospective comparison with current standard of care in a larger clinical trial.”
Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people’s ability to store and use information. The results of the Phase 2a study demonstrate that ANAVEX 2-73 improves psychomotor function, attention and working memory. For attention and working memory these improvements were statistically significant with a p-value of p<0.05 and p<0.001, respectively and their magnitude clinically important. To my knowledge, we have not yet seen a drug that has improved quantitatively working memory to such an extent as seen with ANAVEX 2-73”.
Professor Harald Hampel, member of Anavex’s Scientific Advisory Board, and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, France, commented: “The collective data from this Phase 2a trial supports the concept of targeting the sigma-1 receptor with ANAVEX 2-73 with a degree of confidence that we did not foresee. Sigma-1 receptor presents an innovative interventional upstream approach to impact key cellular events believed to contribute to Alzheimer’s disease pathophysiology. The presented Phase 2a data underlines the importance of rigorously investigating a potential efficacy signal on co-primary outcomes such as cognition and function in larger and well-powered trials”.
“We are encouraged by the preliminary safety and efficacy data. We look forward to continuing with PART B of the Phase 2a trial and expect to provide data updates at 12 week, 26 week, 38 week and 52 week time points,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.”
http://www.anavex.com/?news=anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clinical-trial-of-anavex-2-73-in-alzheimers-disease%e2%80%8e
LPC receives 179,598 free shares up front and could receive another 89,799 free shares. The total 269,397 free shares sold, at say $5.00, would give LPC a $1,346,985 profit.
In consideration for entering into the Purchase Agreement, the Company issued to the Selling Security Holder, 179,598 shares of Common Stock as a commitment fee and shall issue up to 89,799 shares pro rata, which commitment fee shares are also being registered hereunder, when and if, the Selling Security Holder purchases at the Company’s discretion the $50,000,000 aggregate commitment. The Purchase Agreement may be terminated by the Company at any time at its discretion without any cost to the Company.
LPC will be able to buy at a slight discount and should be able to make some money on the shares purchased. I don't think LPC will risk holding the shares for very long. After all, they are a financing company. Dr. Missling will have to space sales to them in order to limit the impact of their sales. Had AVXL done a secoundary offering, I'm sure it would have included full warrants. The buyers of secoundary offerings usually dump their shares after the restricted period and hang on to the warrants. The warrants are dilutive and add additional selling pressure when they are sold.
The purchase price per share for each such Regular Purchase will be equal to the lower of:
•the lowest sale price for our common stock on the purchase date of such shares; or
•the arithmetic average of the three lowest closing sale prices for our common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares.
Another term of the agreement-
No Short-Selling or Hedging by Lincoln Park
Lincoln Park has agreed that neither it nor any of its affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the Purchase Agreement.
From PR -
The Company’s common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
http://www.anavex.com/?news=anavex-prepares-for-uplisting-to-nasdaq-announces-reverse-stock-split
The prospectus that included LPC was filed on 10/23/15 -
As filed with the Securities and Exchange Commission on October 23, 2015
Registration No.____-_______
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
The information in this prospectus is not complete and may be changed. This prospectus is included in a registration statement that we filed with the Securities and Exchange Commission. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.
http://www.sec.gov/Archives/edgar/data/1314052/000161577415003018/s102056_forms3.htm
This is one of the most flagrant misrepresentations of fact that I have ever read -
If you're disappointed by that, then beef about the Company's legal team. You can bet that Dr. Missling sought advise on the subpoena disclosure.
If you expect Anavex's CEO to act like the fluff pumping CEO that lies to investors on a regular basis, you are going to be very disappointed.
Fidelity news feed -
Anavex Life Sciences Corp Jumps 5% on Positive Data on ANAVEX 2-73 in Rett Syndrome
MIDNIGHT TRADER 2:03 PM ET 2/25/2016
Symbol Last Price Change
AVXL 4.433down +0.193 (+4.55%)
QUOTES AS OF 03:02:58 PM ET 02/25/2016
03:03 PM EST, 02/25/2016 (MT Newswires) -- Anavex Life Sciences Corp(AVXL) shares were higher nearly 5% on Thursday after announcing positive data on ANAVEX 2-73 in an exploratory study in a Rett syndrome model at the 2016 Epilepsy Pipeline Conference.
"The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome. There is a tremendous need for therapeutic solutions for the individuals living with Rett syndrome and their families, and we are very encouraged by the data we have seen with ANAVEX 2-73," chief science officer Steven Kaminsky said in a statement.
Anavex shares traded in the lower half of their 52-week range of $0.68 - $14.84.
Price: 4.45, Change: +0.21, Percent Change: +4.83
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Yes, very good results!
Also, I like this from the PR -
About Rettsyndrome.org
Rettsyndrome.org is accelerating research for treatments and a cure for Rett syndrome. As the world’s leading private funder of Rett research, they have funded more than $35 million in peer-reviewed research grants and programs to date. They are a 501(c) 3 organization, earning Charity Navigator’s most prestigious 4-star rating. Rettsyndorme.org empowers families to make a difference. Visit www.rettsyndrome.org to learn more, or call (800) 818-7388 (RETT).